Xynos Konstantinos 4

What Happened Konstantinos Xynos, Chief Medical Officer of Replimune Group (REPL), reported the sale of 14,023 shares on 2026-05-18 for total proceeds of approximately $71,237. The filing lists a weighted average price of $5.08 per share, and the sale was reported under transaction code "S" (sale).

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-20 (appears timely for a Form 4 filing).
• Shares sold: 14,023; reported aggregate proceeds: $71,237.
• Price details: weighted average reported as $5.08; footnote says shares were sold in multiple transactions at prices ranging $5.01–$5.08.
• Footnote: Sale was a "sell to cover" to satisfy tax withholding on partial RSU vesting and was made under an irrevocable provision in the award agreement (not a discretionary sale).
• Shares owned after the transaction: Not disclosed in the information provided in this summary.

Context This was a tax-withholding sale tied to RSU vesting (routine, non-discretionary), not an open-market investment decision. Retail investors typically treat such sell-to-cover transactions as administrative and not a signal of the insider's view on the company's prospects.